G

Greenfern Industries Ltd
NZX:GFI

Watchlist Manager
Greenfern Industries Ltd
NZX:GFI
Watchlist
Price: 0.023 NZD Market Closed
Market Cap: NZ$2.9m

Relative Value

GFI doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of GFI.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GFI Relative Value
Base Case
Not Available
G
Worst Case
Base Case
Best Case

Multiples Across Competitors

GFI Competitors Multiples
Greenfern Industries Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
Greenfern Industries Ltd
NZX:GFI
2.7m NZD 6 -1.7 -2.4 -2.4
US
Eli Lilly and Co
NYSE:LLY
978.7B USD 16.5 53.2 35.7 38.3
US
Johnson & Johnson
NYSE:JNJ
547.3B USD 5.8 20.4 14.2 17.5
CH
Roche Holding AG
SIX:ROG
277.3B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
210B GBP 4.9 30.2 19.7 28.8
CH
Novartis AG
SIX:NOVN
220.8B CHF 5 19.4 15.6 20.1
US
Merck & Co Inc
NYSE:MRK
273B USD 4.3 14.4 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11.1 12.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
150.2B USD 2.4 15.3 7.7 10.5
FR
Sanofi SA
PAR:SAN
95.7B EUR 1.7 8 7.6 7.6
P/E Multiple
Earnings Growth PEG
NZ
G
Greenfern Industries Ltd
NZX:GFI
Average P/E: 22.9
Negative Multiple: -1.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.2
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.4
14%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
7.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.3
27%
0.6
FR
Sanofi SA
PAR:SAN
8
1%
8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
G
Greenfern Industries Ltd
NZX:GFI
Average EV/EBITDA: 47.9
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.7
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.6
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.6
8%
0.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
G
Greenfern Industries Ltd
NZX:GFI
Average EV/EBIT: 102.7
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.3
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.5
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
CH
Novartis AG
SIX:NOVN
20.1
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
7%
1.5
FR
Sanofi SA
PAR:SAN
7.6
6%
1.3